Determination of HER2 Gene Amplification in Breast Cancer using Dual-color Silver Enhanced in situ Hybridization (dc-SISH) and Comparison with Fluorescence ISH (FISH)

Abstract

Background: The two basic methods that are currently accepted to identify the HER2 status are immunohistochemistry and flyorescence in situ hybridization (FISH) . The aim of this study was to perform the dual-color silver in situ hybridization (dc-SISH) technique as an alternative to FISH. Materials and Methods: A total of 40 invasive breast carcinoma cases were assessed for HER2 gene amplification by FISH and dualcolor SISH. Results: Significant correlation was found in the HER2 expression results obtained with the two approaches (p=0.001, p<0.05). The concordance rate was 92.3%. Conclusions: Foutine practical use of the dc-SISH method, which is much easier to apply, score, and evaluate, has many advantages. HER2 and CEN17 status can be evaluated simultaneously with the newly developed "Dual-Color Probe". All these specifications and the reliable results obtained support the widespread use of SISH technique in clinical practice.

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

“…Adjuvant therapy using a monoclonal antibody against HER2 protein (Trastuzumab) is effective alone and in combination with conventional cytotoxic chemotherapy in patients whose breast carcinomas have amplification of HER2 (Goldenberg, 1999;Shak et al, 1999;PiccartGebhart et al, 2005;Romond et al, 2005;Duman et al, 2012;Tai et al, 2013;Unal et al, 2013). However, the significance of HER2 overexpression and amplification in the initiation and progression of ovarian mucinous carcinoma is less well understood (Weroha et al, 2011), and the treatment with HER2 antagonists has been disappointing (Bookman et al, 2003;Frederick et al, 2009).…”

“…The HER2 gene is involved in intracellular signaling transduction pathways leading to cell growth and differentiation (Di Fiore et al, 1987;Kauraniemi et al, 2006;Unal et al, 2013). Studies have suggested that abnormal expression of HER2 gene by mutation or amplification may play an important role in tumor genesis (Auersperg et al, 2001;Garcia-Velasco et al, 2008;Cuadros and Villegras, 2009;Moatter et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Unal et al, 2013).…”

“…HER2 has been reported to be overexpressed or amplified in a variety of human tumors (Nicholson et al, 2001;Rubin and Yarden, 2001;McAlpine et al, 2009;Ghaffari et al, 2011;Wang et al, 2011;Sardari et al, 2012;Duman et al, 2012;Panagiotou et al, 2012; RESEARCH ARTICLE Pazhoomand et al, 2013;Unal et al, 2013;Ziaian et al, 2014). The clinical significance of HER2 status in many tumor types is not yet clear except for breast, gastric, or gastroesophageal junction cancer patients (Nicholson et al, 2001;Gravalos and Jimeno, 2008;García-Velasco et al, 2008;Moatter et al, 2011;Wang et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013).…”

“…The clinical significance of HER2 status in many tumor types is not yet clear except for breast, gastric, or gastroesophageal junction cancer patients (Nicholson et al, 2001;Gravalos and Jimeno, 2008;García-Velasco et al, 2008;Moatter et al, 2011;Wang et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013). Amplification and overexpression of HER2 have been identified in breast cancer (Slamon et al, 1987;Slamon et al, 1989;Wolff et al, 2007;Ghaffari et al, 2011;Moatter et al, 2011;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013) and are associated with a poor prognosis (Wilson et al, 2002;Erdogan et al, 2003;Nathanson et al, 2003).…”

Gene protein detection platform—a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms

“…This includes methods of dual-color in situ hybridization (DISH) [28,39,40] in which HER2 status is typically determined by detecting HER2 gene copies with silver ISH and chromosome 17 copies with chromogenic red ISH. This gives the pathologists the benefit of counting copies of chromosome 17 and HER2 genes on the same slide in light microscopes that permit concurrent analysis of tissue morphology.…”